| NYTIMES 
 Red Meat May Not Be Enough for Irradiation Companies
 
 By JAMES STERNGOLD
 
 Irradiation has become a way of life in the United States. Though not well
 known, irradiation, or the use of small, tightly controlled doses of nuclear
 energy to kill harmful bacteria, is an increasingly common way to sterilize
 medical products.
 
 In addition, roughly 30 percent of the spices used here are irradiated, as
 are a growing number of cosmetics. Containers of all kinds, including many of
 the tiny plastic cups used for milk at coffee shops, are irradiated. Various
 fruits and vegetables, and poultry, are often irradiated, too.
 
 But this small business received what could be its biggest boost last week,
 when the Food and Drug Administration decided to permit the irradiation of red
 meats. Nonetheless, analysts who follow the companies that perform the
 irradiation are skeptical at best about the FDA move.
 
 Their reasons center on consumer reactions and the cost of building new
 facilities. More generally, while most of them believe some irradiation will
 take place, there are big issues about how much and how fast.
 
 "I guess that clearly this is good news because it opens a whole new
 opportunity for these companies," said Anne Malone, an analyst at Smith
 Barney. "But I'm very cautious. There are a lot of 'what-ifs' still."
 
 Alan P. Jacobs, an analyst at Avalon Research, agreed. "The real issue is
 that it's several years out. You can't put a bottom-line value on it."
 
 Irradiation is usually performed not by the company producing the food or
 item being sterilized, but by specialty companies. The three most prominent
 public companies are the Steris Corp., which is in the business by virtue of
 having recently acquired Isomedix for $142 million, Sterigenics International
 and Food Technology Service.
 
 Sterigenics had sales of $37.7 million last year, but Food Technology, with
 just $200,000 in annual sales, is so small that there is little investment
 interest.
 
 Despite analysts' skepticism, these companies enjoyed a quick jump in their
 share prices after the FDA announcement.
 
 And few experts doubt that irradiation, whose safety and effectiveness are
 accepted by many scientists, will eventually become an increasingly important
 means of protecting consumers from bacteria and other microbes in the
 country's food supply.
 
 A growing share of Americans' food is imported, much of it from countries
 that have lower standards for handling and testing food.
 
 In addition, irradiation could become something of an insurance policy for
 meatpackers, not only protecting consumers from microbes, but protecting the
 companies from lawsuits.
 
 And several recent incidents of food contamination in which many people
 became sick, and in some cases died, have increased the appeal of irradiation.
 
 Hudson Foods, a meatpacker, had to recall 25 million pounds of hamburger
 recently because of suspected contamination with the bacteria E. coli; some of
 that meat ended up at Burger King restaurants. Several years ago, there was a
 similar problem at Jack in the Box restaurants.
 
 Thomas J. Gunderson, an analyst at Piper Jaffray, said: "Because of what has
 happened, the best target market is ground beef. The meat processors are for
 this as a way of avoiding a new level of regulatory bureaucracy."
 
 But despite the recent food poisonings, consumers seem to have only a tepid
 desire for irradiation, and some even worry that the procedure may create its
 own health problems. Some people say irradiation may affect how foods taste,
 although a number of experts say this is not the case. These views are not
 lost on some meatpackers.
 
 Even if the irradiation of red meat catches on, one company's efforts to
 prepare for that prospect point up the difficulties. James Williams, the chief
 financial officer of Sterigenics International, which is based in Fremont,
 Calif., said 8 of the company's 12 facilities were currently used for
 sterilizing medical equipment and 4 for packaging, spices and cosmetics. It
 will have to build many new facilities close to the meatpacking plants to take
 advantage of the new business that may develop.
 
 That is a problem because the facilities can take a long time to construct,
 usually 12 to 18 months. The facilities require a hole at least 10 feet deep
 and a protective concrete barrier roughly six feet thick. And special
 approvals are needed to handle the cobalt or other radioactive materials used
 to irradiate the products.
 
 Williams said that to hasten the process, Sterigenics had developed what it
 calls a mini-cell. The mini-cells can be built in 6 to 12 months, and thus can
 quicken the company's move into the kind of business that Sterigenics needs to
 grow.
 
 "The nonmedical area is going to grow much more rapidly than the medical
 side," Williams said. "There are no new entries we see into the medical area."
 
 But Jacobs warned that, if the business did pick up quickly, more companies
 could pour into it and cut margins. "This could become a commodity business,"
 Jacobs said. "The barriers to entry are pretty low. The technology is not
 really new and it is well understood. It just takes capital and time to build
 the facilities."
 
 Also, Steris and Sterigenics are not strong bets because they are trading at
 full value, Jacobs said. The stock of Steris, which is based in Mentor, Ohio,
 closed on Friday at $48.875, or 27 times its estimated earnings per share next
 year. Sterigenics closed at $19.75, or 27 times 1998 estimated earnings.
 
 Ms. Malone was far more upbeat, largely because of the prospects for slow
 but steady growth in Steris' basic business of making infection-control
 products for the health care industry. She said she expects its stock to rise
 to about $60 within the next 12 months, adding that, if the company is able to
 quickly build a business irradiating red meat, the stock price will get
 another boost.
 
 Gunderson said he was modestly optimistic about Sterigenics, which is
 growing nicely and whose stock has already risen considerably from its initial
 public offering of $12 a share in August. He said he expects Sterigenics to
 rise to perhaps the mid- to high $20s over the next 12 months.
 
 Sunday, December 7, 1997
 Copyright 1997 The New York Times
 |